Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS
Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Dirk Schadendorf(National Center for Tumor Diseases), Sebastian Haferkamp(University Hospital Regensburg), R.U. Wahl(Universitätsklinikum Aachen), Friedegund Meier(National Center for Tumor Diseases), H. J. Schulze(Fachklinik Hornheide), Axel Hauschild(University Hospital Schleswig-Holstein), Carola Berking(Universitätsklinikum Erlangen), Ulrike Leiter(University of Tübingen), Rudolf Herbst(Helios Klinikum Erfurt), Monika Hackl(Universidad de Granada), Claas Ulrich(Charité - Universitätsmedizin Berlin)
Cited by 22
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k